Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk

Rejuvenation Research

Volumn 18, Issue 1, 2015, Pages 48-56

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a   Fukami, Kei ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CELL SURFACE RECEPTOR; LIGAND; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

AGING; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; COLORECTAL CANCER; DIABETES MELLITUS; HUMAN; INTERVENTION STUDY; LIVER CELL CARCINOMA; LUNG CANCER; MEDLINE; MELANOMA; NEOPLASM; NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; DISEASE COURSE; INFLAMMATION; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LIGANDS; LYSINE; MELANOMA; MICE; NEOPLASM METASTASIS; NEOPLASMS; OXIDATIVE STRESS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84923351084     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2014.1625     Document Type: Article

References (128)

1. Stattin P, Björ O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-567.
2. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-1123.
3. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006;118:2105-2109.
4. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev 2007;16:83-89.
5. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841.
6. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-2299.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
8. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991;266:11654-11660.
9. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991;266:11649-11653.
10. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995;70:10017-10026.
11. Bucala, Cerami A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992;23:1-34.
12. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003;419:63-79.
13. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87-101.
14. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600.
15. Schmidt AM, Stern D. Atherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2000;2:430-436.
16. Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: Promotion, progression, and prevention. Ann NY Acad Sci 1997;811:115-127.
17. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008;14:973-978.
18. Yamagishi S, Nakamura K, Matsui T, Ueda S, Noda Y, Imaizumi T. Inhibitors of advanced glycation end products (AGEs): Potential utility for the treatment of cardiovascular disease. Cardiovasc Ther 2008;26:50-58.
19. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): A novel therapeutic target for diabetic vascular complications. Curr Pharm Des 2008;14:487-495.
20. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008;14:940-945.
21. Unoki H, Yamagishi S. Advanced glycation end-products and insulin resistance. Curr Pharm Des 2008;14:977-979.
22. Hyogo H, Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008;14:969-972.
23. Glenn JV, Stitt AW. The role of advanced glycation end products in retinal ageing and disease. Biochim Biophys Acta 2009;1790:1109-1116.
24. Puddu A, Viviani GL. Advanced glycation endproducts and diabetes. Beyond vascular complications. Endocr Metab Immune Disord Drug Targets 2011;11:132-140.
25. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. Clin Exp Med 2011;11:131-135.
26. Yamagishi S, Matsui T. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Curr Drug Targets 2010;11:875-881.
27. Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009;60:174-178.
28. Fukami K, Yamagishi S, Sakai K, Kaida Y, Adachi T, Ando R, Okuda S. Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis. Rejuvenation Res 2013;16:460-466.
29. Tahara N, Yamagishi S, Mizoguchi M, Tahara A, Imaizumi T. Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. Rejuvenation Res 2013;16:344-351.
30. Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des 2014;20:2395-2402.
31. Yamagishi S. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetesassociated disorders. Rejuvenation Res 2012;15:564-572.
32. Adeline LYT, Josephine MF, Mark EC. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007;27:130-143.
33. Chakraborty S, Karmakar K, Chakravortty D. Cells producing their own nemesis: Understanding methylglyoxal metabolism. IUBMB Life 2014;66:667-678.
34. Geng X, Ma J, Zhang F, Xu C. Glyoxalase I in tumor cell proliferation and survival and as a potential target for anticancer therapy. Oncol Res Treat 2014;37:570-574.
35. Antognelli C, Mezzasoma L, Fettucciari K, Talesa VN. A novel mechanism of methylglyoxal cytotoxicity in prostate cancer cells. Int J Biochem Cell Biol 2013;45:836-844.
36. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16:1928-1930.
37. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2008;75:130-134.
38. Yamagishi SI, Nakamura K, Matsui T, Yoshida T, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE) - induced angiogenesis in vitro. Horm Metab Res 2007;39:233-235.
39. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen speciesmediated vascular endothelial growth factor expression. J Biol Chem 2006;281:20213-20220.
40. Niiya Y, Abumiya T, Yamagishi S, Takino J, Takeuchi M. Advanced glycation end products increase permeability of brain microvascular endothelial cells through reactive oxygen species-induced vascular endothelial growth factor expression. J Stroke Cerebrovasc Dis 2012;21:293-298.
41. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Okuda S, Imaizumi T. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res 2008;40:10-15.
42. Niiya Y, Abumiya T, Shichinohe H, Kuroda S, Kikuchi S, Ieko M, Yamagishi S, Takeuchi M, Sato T, Iwasaki Y. Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species. Brain Res 2006;1108:179-187.
43. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003;46:284-287.
44. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 2013;12:125.
45. Ishibashi Y, Matsui T, Ueda S, Fukami K, Yamagishi S. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol 2014;13:60.
46. Senger DR, Van De Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF: Vascular permeability factor in tumor biology. Cancer Metastasis Rev 1993;12:303-324.
47. Torisu H, Ono M, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000;85:182-188.
48. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6:3282-3289.
49. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, Haruma K, Chayama K: Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002;102:220-224.
50. Hoshina D, Abe R, Yamagishi SI, Shimizu H. The role of PEDF in tumor growth and metastasis. Curr Mol Med 2010;10:292-295.
51. Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H, Imaizumi T. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. AmJ Pathol 2004;165:1865-1874.
52. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998;41:1435-1441.
53. Enomoto M, Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A, Hiratsuka A, Takajo Y, Imaizumi T. Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism 2006;55:912-917.
54. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006;3:73-77.
55. Zhang H, Tang L, Chen S, Yang Y, Chen M, Luo J. Effect of advanced glycation end products on the expression of hypoxia-inducible factor-1a and vascular endothelial growth factor proteins in RF/6A cells. Exp Ther Med 2013;5:1519-1522.
56. Bondeva T, Heinzig J, Ruhe C, Wolf G. Advanced glycated end-products affect HIF-transcriptional activity in renal cells. Mol Endocrinol 2013;27:1918-1933.
57. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001;276:43836-43841.
58. Chang JS, Wendt T, Qu W, Kong L, Zou YS, Schmidt AM, Yan SF. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res 2008;102:905-913.
59. Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, Anwar T, Rosa R, Indelicato M, Fini M, Pucci B, Russo MA. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa} B. Carcinogenesis 2011;32:1167-1175.
60. Pichiule P, Chavez JC, Schmidt AM, Vannucci SJ. Hypoxiainducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia. J Biol Chem 2007;282:36330-36340.
61. Chen H, Wu L, Li Y, Meng J, Lin N, Yang D, Zhu Y, Li X, Li M, Xu Y, Wu Y, Tong X, Su Q. Advanced glycation end products increase carbohydrate responsive element binding protein expression and promote cancer cell proliferation. Mol Cell Endocrinol 2014;395:69-78.
62. Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E, D'Agati V, Schmidt AM. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 2008;283:34457-34468.
63. Yamamoto K, Murata H, Putranto EW, Kataoka K, Motoyama A, Hibino T, Inoue Y, Sakaguchi M, Huh NH. DOCK7 is a critical regulator of the RAGE-Cdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells. Oncol Rep 2013;29:1073-1079.
64. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs) - induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm Metab Res 2013;45:387-390.
65. Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des 2014;20:2395-2402.
66. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010;2:1184-1195.
67. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-2299.
68. Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007;4:181-189.
69. Perrot-Applanat M, Di Benedetto M. Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion. Cell Adh Migr 2012;6:547-553.
70. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 2007;121:856-862.
71. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167.
72. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
73. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-1308.
74. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: A meta-analysis and critical literature review. Breast Cancer Res Treat 2012;135:639-646.
75. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care 2012;35:299-304.
76. Radia AM, Yaser AM, Ma X, Zhang J, Yang C, Dong Q, Rong P, Ye B, Liu S, Wang W. Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. Int J Mol Sci 2013;14:7959-7978.
77. Lata K, Mukherjee TK. Knockdown of receptor for advanced glycation end products attenuate 17a-ethinylestradiol dependent proliferation and survival of MCF-7 breast cancer cells. Biochim Biophys Acta 2014;1840:1083-1091.
78. Chiavarina B, Nokin MJ, Durieux F, Bianchi E, Turtoi A, Peulen O, Peixoto P, Irigaray P, Uchida K, Belpomme D, Delvenne P, Castronovo V, Bellahcène A. Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget 2014;5:5472-5482.
79. Antognelli C, Palumbo I, Aristei C, Talesa VN. Glyoxalase I inhibition induces apoptosis in irradiated MCF-7 cells via a novel mechanism involving Hsp27, p53 and NF-jB. Br J Cancer 2014;111:395-406.
80. Nass N, Brömme HJ, Hartig R, Korkmaz S, Sel S, Hirche F, Ward A, Simm A, Wiemann S, Lykkesfeldt AE, Roessner A, Kalinski T. Differential response to a-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells. PLoS One 2014;9:e101473.
81. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185-193.
82. Liu LS, Colegio OR. Molecularly targeted therapies for melanoma. Int J Dermatol 2013;52:523-530.
83. Abe R, Fujita Y, Yamagishi S. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini Rev Med Chem 2007;7:649-661.
84. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008;14:940-945.
85. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, Sasaki N, Yamagishi S, Takeuchi M, Shimizu H. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004;122:461-467.
86. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992;355:564-566.
87. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, Group VISiONCT. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
88. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 2011;106:539-547.
89. Kaida Y, Fukami K, Matsui T, Higashimoto Y, Nishino Y, Obara N, Nakayama Y, Ando R, Toyonaga M, Ueda S, Takeuchi M, Inoue H, Okuda S, Yamagishi SI. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes 2013;62:3241-3250.
90. Ojima A, Matsui T, Maeda S, Takeuchi M, Inoue H, Higashimoto Y, Yamagishi S. DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab Invest 2014;94:422-429.
91. Leclerc E, Heizmann CW, Vetter SW. RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen Physiol Biophys 2009;28 Spec No Focus: F65-75.
92. Zhu L, Ito T, Nakahara T, Nagae K, Fuyuno Y, Nakao M, Akahoshi M, Nakagawa R, Tu Y, Uchi H, Furue M. Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma. J Dermatol 2013;40:973-979.
93. Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010;337:251-258.
94. Arumugam T, Logsdon CD. S100P: A novel therapeutic target for cancer. Amino Acids 2011;41:893-899.
95. Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther 2014;141:347-357.
96. Van Beijnum JR, Nowak-Sliwinska P, Van Den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis enforced by autocrine regulation of high-mobility group box-1. Oncogene 2013;32:363-374.
97. Popa I, Ganea E, Petrescu SM. Expression and subcellular localization of RAGE in melanoma cells. Biochem Cell Biol 2014;92:127-136.
98. Meghnani V, Vetter SW, Leclerc E. RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line. Biochim Biophys Acta 2014;1842:1017-1027.
99. Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H. Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun 1996;222:700-705.
100. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Bierhaus A, Lotze MT, Zeh HJ. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010;17:666-676.
101. Kang R, Loux T, Tang D, Schapiro NE, Vernon P, Livesey KM, Krasinskas A, Lotze MT, Zeh HJ 3rd. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci USA 2012;109:7031-7036.
102. Kang R, Tang D, Lotze MT, Zeh HJ 3rd. AGER/RAGEmediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy 2012;8:989-991.
103. Ji YF, Huang H, Jiang F, Ni RZ, Xiao MB. S100 family signaling network and related proteins in pancreatic cancer (Review). Int J Mol Med 2014;33:769-776.
104. Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, Virtamo J, Stolzenberg-Solomon RZ. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res 2011;71:3582-3589.
105. Grote VA, Nieters A, Kaaks R, Tjønneland A, Roswall N, Overvad K, Nielsen MR, Clavel-Chapelon F, Boutron-Ruault MC, Racine A, Teucher B, Lukanova A, Boeing H, Drogan D, Trichopoulou A, Trichopoulos D, Lagiou P, Palli D, Sieri S, Tumino R, Vineis P, Mattiello A, Argüelles Suárez MV, Duell EJ, Sánchez MJ, Dorronsoro M, Huerta Castaño JM, Barricarte A, Jeurnink SM, Peeters PH, Sund M, Ye W, Regner S, Lindkvist B, Khaw KT, Wareham N, Allen NE, Crowe FL, Fedirko V, Jenab M, Romaguera D, Siddiq A, Bueno-de-Mesquita HB, Rohrmann S. The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: A casecontrol study within the prospective EPIC Cohort. Cancer Epidemiol Biomarkers Prev 2012;21:619-628.
106. Takino J, Yamagishi S, Takeuchi M. Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol 2012;18:1781-1788.
107. Sakuraoka Y, Sawada T, Okada T, Shiraki T, Miura Y, Hiraishi K, Ohsawa T, Adachi M, Takino J, Takeuchi M, Kubota K. MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells. World J Gastroenterol 2010;16:5334-5341.
108. Hiwatashi K, Ueno S, Abeyama K, Kubo F, Sakoda M, Maruyama I, Hamanoue M, Natsugoe S, Aikou T. A novel function of the receptor for advanced glycation endproducts (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol 2008;15:923-933.
109. Ito R, Ishii Y, Wakiyama S, Shiba H, Fujioka S, Misawa T, Ishida Y, Hano H, Yanaga K. Prognostic significance of receptor for advanced glycation end products expression in hepatocellular carcinoma after hepatectomy. J Surg Res 2014; doi: 10.1016/j.jss.2014.06.028.
110. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A. Highmobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 2012;55:1863-1875.
111. Kan H, Yamagishi SI, Ojima A, Fukami K, Ueda S, Takeuchi M, Hyogo H, Aikata H, Chayama K. Elevation of serum levels of advanced glycation end products in patients with non-B or non-C hepatocellular carcinoma. J Clin Lab Anal 2014; doi: 10.1002/jcla.21797.
112. Moy KA, Jiao L, Freedman ND, Weinstein SJ, Sinha R, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology 2013;57:2338-2345.
113. Zill H, Günther R, Erbersdobler HF, Fölsch UR, Faist V. RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem Biophys Res Commun 2001;288:1108-1111.
114. Shimomoto T, Luo Y, Ohmori H, Chihara Y, Fujii K, Sasahira T, Denda A, Kuniyasu H. Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet. J Gastroenterol 2012;47:1073-1083.
115. Heijmans J, Büller NV, Hoff E, Dihal AA, Van Der Poll T, Van Zoelen MA, Bierhaus A, Biemond I, Hardwick JC, Hommes DW, Muncan V, Van Den Brink GR. Rage signalling promotes intestinal tumourigenesis. Oncogene 2013;32:1202-1206.
116. Di Norcia J, Moroziewicz DN, Ippagunta N, Lee MK, Foster M, Rotterdam HZ, Bao F, Zhou YS, Yan SF, Emond J, Schmidt AM, Allendorf JD. RAGE signaling significantly impacts tumorigenesis and hepatic tumor growth in murine models of colorectal carcinoma. J Gastrointest Surg 2010;14:1680-1690.
117. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2011;20:1430-1438.
118. Van Heijst JW, Niessen HW, Musters RJ, Van Hinsbergh VW, Hoekman K, Schalkwijk CG. Argpyrimidinemodified heat shock protein 27 in human non-small cell lung cancer: A possible mechanism for evasion of apoptosis. Cancer Lett 2006;241:309-319.
119. Takino J, Yamagishi S, Takeuchi M. Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol 2010;2010:739852.
120. Bartling B, Hofmann HS, Sohst A, Hatzky Y, Somoza V, Silber RE, Simm A. Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end products in non-small cell lung carcinoma. Mol Med 2011;17:980-989.
121. Miki S, Kasayama S, Miki Y, Nakamura Y, Yamamoto M, Sato B, Kishimoto T. Expression of receptors for advanced glycosylation end products on renal cell carcinoma cells in vitro. Biochem Biophys Res Commun 1993;196:984-989.
122. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K, Kuniyasu H. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007;450:287-295.
123. Sasahira T, Kirita T, Bhawal UK, Yamamoto K, Ohmori H, Fujii K, Kuniyasu H. Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology 2007;51:166-172.
124. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W. Expression of receptors for advanced glycation endproducts (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-170.
125. Xu XC, Abuduhadeer X, Zhang WB, Li T, Gao H, Wang YH. Knockdown of RAGE inhibits growth and invasion of gastric cancer cells. Eur J Histochem 2013;57:e36.
126. Elangovan I, Thirugnanam S, Chen A, Zheng G, Bosland MC, Kajdacsy-Balla A, Gnanasekar M. Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun 2012;417:1133-1138.
127. Zhao CB, Bao JM, Lu YJ, Zhao T, Zhou XH, Zheng DY, Zhao SC. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res 2014;4:369-377.
128. Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-360.